Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2022 | Poziotinib for HER2-positive metastatic breast cancer

Yeon Hee Park, MD, PhD, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, presents final updates from the Phase II NOV120101-203 trial (NCT02418689) evaluating poziotinib in patients with HER2-positive metastatic breast cancer, highlighting the potential benefit of this pan-HER tyrosine kinase inhibitor following progression using trastuzumab deruxtecan. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.